Yoon Hang Kim, MD, MPH  •  www.directintegrativecare.com

Introduction

Few laboratory tests are ordered more often, or interpreted more reflexively, than thyroid-stimulating hormone (TSH). Major guidelines from the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) identify serum TSH as the single best screening test for primary thyroid dysfunction in ambulatory adults, and for most outpatient scenarios this is accurate.¹⁻² Yet clinicians who care for patients with persistent fatigue, autoimmune disease, chronic illness, or unexplained symptoms regularly encounter a different reality: a “normal” TSH that does not match the clinical picture. The question is not whether TSH is a good test—it is—but when it is enough, and when a broader panel (free T4, free T3, anti-thyroid peroxidase antibodies [TPOAb], anti-thyroglobulin antibodies [TgAb], and in selected cases reverse T3) will yield a more informative answer.

This article reviews the evidence-based situations in which TSH alone suffices, the situations in which it quietly fails, and offers a practical framework that integrates guideline-based endocrinology with the clinical realities encountered in integrative and functional medicine practice.

The Case for TSH Alone

TSH is exquisitely sensitive to changes in circulating thyroid hormone. Because pituitary thyrotropes respond logarithmically to small changes in free T4, TSH typically rises or falls before free T4 moves outside its reference range. The 2012 AACE/ATA hypothyroidism guidelines state that “a serum thyrotropin is the single best screening test for primary thyroid dysfunction for the vast majority of outpatient clinical situations” and recommend that free T4 be added only when TSH is abnormal or when central hypothyroidism is suspected.²

For two specific scenarios, TSH alone is generally sufficient:

• Screening asymptomatic low-risk adults for primary thyroid dysfunction.
• Monitoring stable levothyroxine replacement once a euthyroid dose has been established, typically with periodic measurement every 6 to 12 months per AACE/ATA guidance.²

In both cases, the clinical question is narrow: is the pituitary-thyroid axis in an acceptable steady state? TSH answers that question reliably and cost-effectively.

Where TSH Alone Quietly Fails

The limitations of a TSH-only strategy become apparent in four recurring clinical situations.

1. The Reference Range Problem

Population TSH reference ranges—typically 0.4 to 4.5 mIU/L—derive from large cross-sectional surveys, including the National Health and Nutrition Examination Survey (NHANES III).³ However, the original NHANES III dataset included individuals with occult autoimmune thyroid disease, which skewed the upper reference limit higher than would be observed in a disease-free reference population. When individuals with positive thyroid antibodies, personal or family history of thyroid disease, and medication effects were excluded, the upper limit of normal fell closer to 2.5 mIU/L in younger adults.³

Clinically, this means a patient with a TSH of 3.8 mIU/L, fatigue, cold intolerance, hair loss, and positive TPO antibodies is not reliably reassured by a “normal” laboratory result. The reference range may include many individuals with early, compensated autoimmune thyroid disease.

2. Hashimoto’s and the Euthyroid Autoimmune Phase

Chronic autoimmune thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions.⁴ TPOAb and TgAb can be detectable years—sometimes decades—before TSH rises above the reference range. The 2012 AACE/ATA guidelines explicitly recommend TPOAb measurement in the evaluation of patients with subclinical hypothyroidism, recurrent miscarriage, and suspected autoimmune thyroiditis.² If the clinical question is “does this patient have autoimmune thyroid disease?” then TSH alone is the wrong test; antibody testing is required to detect the disease in its preclinical phase.

3. Impaired T4-to-T3 Conversion in Levothyroxine-Treated Patients

Perhaps the most clinically important limitation of a TSH-only strategy is in the follow-up of patients on levothyroxine (LT4) monotherapy. Peterson, McAninch, and Bianco analyzed NHANES data and found that levothyroxine-treated patients with a normal TSH had measurably different circulating thyroid hormone profiles compared with matched euthyroid controls: lower free T3, lower T3:T4 ratios, higher body mass index, and greater use of statins, beta blockers, and antidepressants.⁵ Gullo and colleagues similarly reported that levothyroxine monotherapy did not restore normal serum T3 concentrations in a substantial subset of athyreotic patients, despite normalization of TSH.⁶

These findings help explain the well-documented phenomenon, quantified by Peterson and colleagues in a large online survey of more than 12,000 hypothyroid patients, in which a meaningful subset of levothyroxine-treated patients report persistent symptoms and reduced quality of life despite biochemical “euthyroidism.”⁷ The 2014 ATA hypothyroidism treatment guidelines acknowledge this reality and note that combination LT4/LT3 therapy may be considered in selected patients who do not feel well on LT4 alone, a position further developed in the 2021 ATA/ETA/BTA consensus document on evidence-based use of LT4/LT3 combinations.⁸⁻⁹

Selecting such patients requires measuring free T3—and ideally the free T3 to reverse T3 ratio—not simply looking at TSH.

4. Central Hypothyroidism

Central (secondary) hypothyroidism caused by pituitary or hypothalamic disease produces low or inappropriately normal TSH with low free T4. The 2012 AACE/ATA guidelines state unequivocally that TSH is “not sufficient for assessing hospitalized patients or when central hypothyroidism is either present or suspected,” and that free T4 assessment should guide therapy in central disease, targeting values above the mid-normal range of the assay.² Missing central hypothyroidism is a common pitfall of reflexive TSH-only testing.

5. Non-Thyroidal Illness and Reverse T3

Reverse T3 (rT3) remains the most contested test in this panel. Major endocrine society guidelines do not recommend rT3 for the routine diagnosis of hypothyroidism in outpatient practice, and it should not be used as a screening test.¹ However, rT3 rises in non-thyroidal illness syndrome, caloric restriction, significant physiologic stress, and some chronic inflammatory states, reflecting a shift in peripheral deiodinase activity.⁴ In the complex patient—chronic fatigue, post-viral syndromes, Long COVID, chronic inflammatory response syndrome, significant HPA-axis dysregulation—the free T3 to reverse T3 ratio can provide useful context about tissue-level thyroid economy, even though it has not been incorporated into mainstream endocrinology guidelines. It is a contextual test, not a screening test.

A Practical Framework

Integrating guideline-based endocrinology with clinical realism, the following framework can guide test selection:

Screening the asymptomatic adult

TSH alone. Reflex to free T4 if TSH is abnormal.¹⁻²

Monitoring stable levothyroxine replacement

TSH every 6 to 12 months. Add free T4 if symptoms develop or the dose is changed.² Consider free T3 in patients with persistent symptoms despite normal TSH.⁵⁻⁷

New symptomatic workup

Order TSH, free T4, free T3, TPOAb, and TgAb together. This single panel answers four questions at once: Is the pituitary-thyroid axis intact? Is there a conversion problem? Is there autoimmunity? Is there a discordance between TSH and peripheral hormones? It spares the patient a second blood draw when the initial TSH is abnormal or borderline, and it detects the euthyroid autoimmune phase that TSH alone will miss.

Complex chronic illness or treatment-resistant symptoms

Full panel including reverse T3 and free T3:rT3 ratio, interpreted in the context of the whole clinical picture. This applies to patients with post-viral syndromes, chronic fatigue, significant inflammation, or suspected non-thyroidal illness physiology.

Suspected central hypothyroidism

Free T4 is non-negotiable, as TSH may be normal or low despite clinically significant hypothyroidism.²

Pregnancy and preconception

Trimester-specific TSH reference ranges apply, and free T4 and TPOAb status are relevant for risk stratification of pregnancy loss and obstetric outcomes.²

Conclusion

TSH is the most sensitive test for the pituitary’s assessment of thyroid status. It is not always the most sensitive test for whether a patient has a thyroid problem. Those are two different questions, and the distinction should drive test selection. For asymptomatic screening and stable replacement monitoring, TSH alone is appropriate, cost-effective, and concordant with major guidelines. For symptomatic patients, those with autoimmune features, those on levothyroxine who remain unwell, or those with complex chronic illness, a broader panel—free T4, free T3, TPOAb, TgAb, and sometimes reverse T3—more accurately answers the clinical question being asked. Thoughtful test selection, interpreted in the context of a careful history and physical examination, remains the foundation of sound thyroid care.

References

1. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–1751. doi:10.1089/thy.2014.0028

2. Garber JR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22(12):1200–1235. doi:10.1089/thy.2012.0205

3. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499. doi:10.1210/jcem.87.2.8182

4. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550–1562. doi:10.1016/S0140-6736(17)30703-1

5. Peterson SJ, McAninch EA, Bianco AC. Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? J Clin Endocrinol Metab. 2016;101(12):4964–4973. doi:10.1210/jc.2016-2660

6. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011;6(8):e22552. doi:10.1371/journal.pone.0022552

7. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–721. doi:10.1089/thy.2017.0681

8. Wiersinga WM, Duntas L, Fadeyev V, Gilis-Januszewska A, Jonklaas J, Pietila P. 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012;1(2):55–71. doi:10.1159/000339444

9. Jonklaas J, Bianco AC, Cappola AR, et al. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid. 2021;31(2):156–182. doi:10.1089/thy.2020.0720